[go: up one dir, main page]

PE20040640A1 - Compuestos de tiazol como inhibidores de la enzima gamma secretasa - Google Patents

Compuestos de tiazol como inhibidores de la enzima gamma secretasa

Info

Publication number
PE20040640A1
PE20040640A1 PE2003001021A PE2003001021A PE20040640A1 PE 20040640 A1 PE20040640 A1 PE 20040640A1 PE 2003001021 A PE2003001021 A PE 2003001021A PE 2003001021 A PE2003001021 A PE 2003001021A PE 20040640 A1 PE20040640 A1 PE 20040640A1
Authority
PE
Peru
Prior art keywords
alkyl
phenyl
thiazol
difluoro
cycloalkyl
Prior art date
Application number
PE2003001021A
Other languages
English (en)
Inventor
Michael Leon Corman
Yuhpyng Liang Chen
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20040640A1 publication Critical patent/PE20040640A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54—Nitrogen and either oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTOS DE TIAZOL DE FORMULA (I), DONDE A ES -C(=O)C(=O)-, -C(=O)NR9-, -C(=O)Z-, -C(=S)Z-, ENTRE OTROS; Z ES -CH2-, -CH(OH)-, -CH(OC(=O)R11)-, ENTRE OTROS; R1 ES ALQUILO(C1-C20), ALCOXI(C1-C20), CICLOALQUILO(C3-C8), CICLOALQUENILO(C4-C8), BI O TRICICLOALQUILO(C5-C11), ENTRE OTROS; R2 ES H, ALQUILO(C1-C4), -C(=O)(ALQUILO(C1-C4)), ARILO(C6-C10), ENTRE OTROS; R3 ES ALQUILO(C1-C6), ALQUENILO(C2-C6), ALQUINILO(C2-C6), -(ALQUILENO(C0-C4))-(CICLOALQUILO(C3-C6)), ENTRE OTROS; R4 ES H, D, F, ALQUILO(C1-C4) O R3 Y R4 FORMAN UN CICLOPROPILO, CICLOBUTILO, CICLOHEXILO, MORFOLINO, ENTRE OTROS; R6 ES -H, -ALQUILO(C1-C20), HALOGENO, -CN, -CF3, -C(=O)R11, ENTRE OTROS; R7 ES H, HALOGENO, -CN, -NO2, -CF3, ALQUILO (C1-C20), ALCOXI(C1-C20), O R6 Y R7 FORMAN UN ANILLO ARILO(C6-C10), CICLOALQUILO O CICLOALQUENILO(C6-C8), HETEROCICLOALQUILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 2-[2-(3,5-DIFLUORO-FENIL)-ACETILAMINO]-N-(4-FENIL-TIAZOL-2-IL)-PROPIONAMIDA, ESTER ETILICO DEL ACIDO 2-{2-[2-(3,5-DIFLUORO-FENIL)-ACETILAMINO]-PROPIONILAMINO}-4-FENIL-TIAZOL-5-CARBOXILICO, [5-(1-BUTILAMINO-ETIL)-4-METIL-TIAZOL-2-IL]-AMIDA DEL ACIDO 2-[2-(3,5-DIFLUORO-FENIL)-ACETAMINO]-PENTANOICO, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE LO CONTIENE. ESTOS COMPUESTOS INHIBEN LA PRODUCCION DE Aß-PEPTIDOS DEBIDO A SU ACTIVIDAD INHIBITORIA DE LA ENZIMA GAMMA-SECRETASA Y SON UTILES PARA EL TRATAMIENTO DE TRANSTORNOS NEURODEGENERATIVOS COMO EL MAL DE ALZHEIMER
PE2003001021A 2002-10-09 2003-10-07 Compuestos de tiazol como inhibidores de la enzima gamma secretasa PE20040640A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41740002P 2002-10-09 2002-10-09
US46320903A 2003-06-17 2003-06-17

Publications (1)

Publication Number Publication Date
PE20040640A1 true PE20040640A1 (es) 2004-09-15

Family

ID=35306299

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003001021A PE20040640A1 (es) 2002-10-09 2003-10-07 Compuestos de tiazol como inhibidores de la enzima gamma secretasa

Country Status (28)

Country Link
US (1) US20040152747A1 (es)
EP (1) EP1551815A1 (es)
JP (1) JP2006504796A (es)
KR (1) KR20050070046A (es)
CN (1) CN1688557A (es)
AP (1) AP2005003274A0 (es)
AR (1) AR043051A1 (es)
AU (1) AU2003265068A1 (es)
BR (1) BR0314611A (es)
CA (1) CA2501803A1 (es)
CO (1) CO5550435A2 (es)
CR (1) CR7785A (es)
EC (1) ECSP055719A (es)
GT (1) GT200300219A (es)
IS (1) IS7738A (es)
MA (1) MA27451A1 (es)
MX (1) MXPA05002420A (es)
NL (1) NL1024499C2 (es)
NO (1) NO20052223L (es)
OA (1) OA12937A (es)
PA (1) PA8585001A1 (es)
PE (1) PE20040640A1 (es)
PL (1) PL376171A1 (es)
TN (1) TNSN05104A1 (es)
TW (1) TW200420550A (es)
UY (1) UY28011A1 (es)
WO (1) WO2004033439A1 (es)
ZA (1) ZA200502841B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2842523A1 (fr) * 2002-07-17 2004-01-23 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
CA2524511A1 (en) * 2003-05-12 2004-11-18 Pfizer Products Inc. Isoxazole and isothiazole compounds for the treatment of neurodegenerative disorders
WO2005016267A2 (en) * 2003-08-06 2005-02-24 Pfizer Products Inc. Oxazole compounds for the treatment of neurodegenerative disorders
FR2865206B1 (fr) * 2004-01-16 2009-02-06 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
FR2865207B1 (fr) * 2004-01-16 2008-10-17 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
AU2005209442B2 (en) 2004-01-16 2011-03-31 Sanofi-Aventis Acylaminothiazole derivatives, preparation method thereof and use of same in therapeutics
SI1709018T1 (sl) 2004-01-16 2011-11-30 Sanofi Sa Acilaminotiazolni derivati in njihova uporaba kotbeta-amiloidni inhibitorji
FR2873370B1 (fr) * 2004-07-22 2006-10-20 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
FR2873374B1 (fr) * 2004-07-22 2006-10-20 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
BRPI0509069B8 (pt) * 2004-03-23 2021-05-25 Pfizer Prod Inc compostos de imidazol e composição farmacêutica que os compreende para o tratamento de distúrbios neurodegenerativos
US7220865B2 (en) * 2004-04-01 2007-05-22 Pfizer Inc Isoxazole-and isothiazole-amine compounds for the treatment of neurodegenerative disorders
US7384968B2 (en) * 2004-04-01 2008-06-10 Pfizer Inc. Thiazole-amine compounds for the treatment of neurodegenerative disorders
RU2007109073A (ru) 2004-08-13 2008-09-20 Дженентек, Инк. (Us) Ингибиторы для атф-зависимого фермента на основе тиазола
US7888379B2 (en) 2005-05-24 2011-02-15 Merck Serono Sa Thiazole derivatives and use thereof
FR2887879B1 (fr) * 2005-07-01 2008-09-26 Trophos Sa Nouveaux composes chimiques et leurs utilisations comme medicament,particulierement dans le traitement des maladies neurodegeneratives
EP1940802A2 (en) * 2005-09-22 2008-07-09 Pfizer Products Inc. Imidazole compounds for the treatment of neurological disorders
WO2007064891A1 (en) 2005-12-01 2007-06-07 The Scripps Research Institute Compositions and methods for inducing neuronal differentiation
KR20080091369A (ko) * 2006-01-18 2008-10-10 암젠 인크 단백질 키나제 ｂ （ｐｋｂ） 억제제로서 티아졸 화합물
EP1918286B1 (en) * 2006-11-05 2011-12-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Thiazolhydrazides for treatment of neurodegenerative diseases
GB0701426D0 (en) * 2007-01-25 2007-03-07 Univ Sheffield Compounds and their use
US7919504B2 (en) * 2007-07-17 2011-04-05 Amgen Inc. Thiadiazole modulators of PKB
AU2008276521B2 (en) 2007-07-17 2011-11-03 Amgen Inc. Heterocyclic modulators of PKB
EP2349484A2 (en) 2008-07-15 2011-08-03 Novartis AG Heteroaryl derivatives as dgat1 inhibitors
EP2398771B1 (en) 2009-02-18 2015-07-29 Boehringer Ingelheim International GmbH Heterocyclic compounds which modulate the cb2 receptor
WO2010126002A1 (ja) * 2009-04-28 2010-11-04 塩野義製薬株式会社 ヘテロ環スルホンアミド化合物を含有する医薬
US8299103B2 (en) * 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
JP2013517271A (ja) 2010-01-15 2013-05-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節する化合物
EP2595959B1 (en) 2010-07-22 2015-11-04 Boehringer Ingelheim International GmbH Sulfonyl compounds which modulate the cb2 receptor
CN102351854B (zh) * 2011-07-29 2014-06-04 华中科技大学 氨基噻唑衍生物及制备方法和医药用途
RS58768B1 (sr) * 2013-03-14 2019-06-28 Merck Patent Gmbh Inhibitori glikozidaze
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
CN103408541B (zh) * 2013-07-16 2015-04-01 浙江医药高等专科学校 吲哚取代的噻唑并环己烷类化合物、及其抗肿瘤用途
CN103435573B (zh) * 2013-07-16 2015-04-01 浙江医药高等专科学校 苄基取代的噻唑并环己烷类化合物、其制备方法和用途
GB201401886D0 (en) * 2014-02-04 2014-03-19 Lytix Biopharma As Neurodegenerative therapies
JP7134173B2 (ja) * 2017-06-21 2022-09-09 第一三共株式会社 Ｅｐ３００／ｃｒｅｂｂｐ阻害剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06508135A (ja) * 1991-05-28 1994-09-14 メルク　エンド　カンパニー　インコーポレーテッド 抗変性活性剤としての置換ｎ−カルボキシアルキルペプチジル誘導体
CO5021134A1 (es) * 1998-05-01 2001-03-27 Abbott Lab Inhibidores beta-aminoacidos substituidos de aminopeptida- sa-2 metionina
BR9910092A (pt) * 1998-05-01 2002-01-22 Abbott Lab Inibidores de beta-aminoácido substituìdo de metionina aminopeptidase-2
WO2000024392A1 (fr) * 1998-10-26 2000-05-04 Sumitomo Pharmaceuticals Company, Limited Inhibiteur de la formation de beta-amyloide
AR039059A1 (es) * 2001-08-06 2005-02-09 Sanofi Aventis Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios
FR2842523A1 (fr) * 2002-07-17 2004-01-23 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
NO20052223D0 (no) 2005-05-06
ECSP055719A (es) 2005-07-06
NL1024499C2 (nl) 2004-10-13
CO5550435A2 (es) 2005-08-31
KR20050070046A (ko) 2005-07-05
CR7785A (es) 2005-07-08
TNSN05104A1 (fr) 2007-05-14
MXPA05002420A (es) 2005-10-05
BR0314611A (pt) 2005-07-26
AR043051A1 (es) 2005-07-13
JP2006504796A (ja) 2006-02-09
CA2501803A1 (en) 2004-04-22
PA8585001A1 (es) 2004-12-16
EP1551815A1 (en) 2005-07-13
US20040152747A1 (en) 2004-08-05
OA12937A (en) 2006-10-13
AU2003265068A1 (en) 2004-05-04
GT200300219A (es) 2004-05-18
NL1024499A1 (nl) 2004-04-13
NO20052223L (no) 2005-07-04
IS7738A (is) 2005-03-10
CN1688557A (zh) 2005-10-26
UY28011A1 (es) 2004-04-30
MA27451A1 (fr) 2005-07-01
PL376171A1 (en) 2005-12-27
ZA200502841B (en) 2006-03-29
AP2005003274A0 (en) 2005-06-30
TW200420550A (en) 2004-10-16
WO2004033439A1 (en) 2004-04-22

Similar Documents

Publication Publication Date Title
PE20040640A1 (es) Compuestos de tiazol como inhibidores de la enzima gamma secretasa
PE20051155A1 (es) Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos
CO5700824A2 (es) Nuevos compuestos heterociclicos utiles para el tratamiento de desordenes inflamatorios y alergicos: proceso para su preparacion y composiciones farmaceuticas que los contienen
PE20090041A1 (es) Derivados de triazol como inhibidores de la biosintesis de leucotrienos
MX2011008305A (es) Compuestos de piridazinona.
PE20061123A1 (es) Derivados de amida como inhibidores de la hidrolasa de amida de acido graso
PE20030086A1 (es) Derivados de acidos tiofen dicarboxilicos como inhibidores de histona desacilasa (hdca)
PE20061303A1 (es) Composicion farmaceutica que comprende oxaprozina
KR20080098443A (ko) 세라마이드 키나제 조절
PE20061013A1 (es) Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias
AR054560A1 (es) Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer
MA30456B1 (fr) Nouveau dérivé de coumarine présentant une activité anti-tumorale.
WO2005012269A8 (ja) 新規アゾール化合物
MA32965B1 (fr) Derives de sulfonamides
PE20120058A1 (es) Derivados de imidazopirazina como inhibidores de syk
AR059895A1 (es) Derivados biciclicos de acidos carboxilicos que resultan de utilidad para tratar trastornos metabolicos
NZ602099A (en) Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient
AR047671A1 (es) Compuestos de arilnitrona 2-sustituidos y 4-sustituidos
CA2581865A1 (en) Indazolone derivatives as 11b-hsd1 inhibitors
MX2010000658A (es) Derivados de pirimidina 934.
PE20011290A1 (es) Derivados de benzotiazol como inhibidores del factor de necrosis tumoral (tnf) y/o fosfodiesterasa iv (pdeiv)
PE20091102A1 (es) Moduladores imidazolo-, oxazolo-, y tiazolopirimidina del trpv1
HU229137B1 (en) 8,8a-dihydro-indeno[1,2-d]thiazole derivatives having sulphoneamid- or sulphone substitutents in the 2 position, method for production thereof and use thereof as a medicament
PE20090280A1 (es) Pirazol-pirrolidinas como inhibidores de gamma secretasa
PE20081160A1 (es) Arilsulfonil-pirrolidinas como inhibidores 5-ht6

Legal Events

Date Code Title Description
FA Abandonment or withdrawal